Healthcare tech company Omnicell (NASDAQ:OMCL) reported revenue ahead of Wall Street’s expectations in Q3 2026, but sales were flat year on year at $307.9 million. On the other hand, next quarter’s revenue guidance of $298 million was less impressive, coming in 4.3% below analysts’ estimates. Its non-GAAP profit of $0.58 per share was 38.9% above analysts’ consensus estimates.
Is now the time to buy OMCL? Find out in our full research report (it’s free for active Edge members).
Omnicell (OMCL) Q3 2026 highlights:
- Revenue $307.9 million vs S&P analysts’ estimates of $305.9 million (flat year on year, 0.6% beat)
- Adjusted EPS $0.58 vs S&P analysts’ estimates of $0.42 (38.9% beat)
- Adjusted EBITDA $44.93 million vs analyst estimates of $36.1 million (14.6% margin, 24.5% beat)
- Revenue guidance $298 million at the midpoint for Q4 2026, below analyst estimates of $311.5 million
- Adjusted EPS guidance Management raised its full-year adjusted EPS guidance to $2.52 at the midpoint, a 13.3% increase
- EBITDA guidance $190 million at the midpoint for the full year, above analyst estimates of $181.3 million
- Operating margin 4.9%, up from 2.7% in the same quarter last year
- Market capitalization $1.68 billion
StockStory’s take
Omnicell’s third quarter was marked by disciplined operational execution, which the market responded to positively. Management attributed performance to ongoing cost efficiency initiatives and favorable customer and product mix, helping offset flat sales. CEO Randall Lipps pointed to robust engagement with health systems and highlighted the growing importance of automation and enterprise-wide medication management as fundamental to Omnicell’s value proposition. The company also benefited from expanding leasing programs and maintained momentum in its automated dispensing cabinet business, which remains deeply embedded in U.S. acute care settings.
Looking ahead, Omnicell’s guidance reflects caution around the timing of large customer implementations, as well as measured decision-making cycles among health systems. Management sees the refresh cycle for Titan XT hardware and the transition to the OmniSphere cloud platform as multi-year growth drivers, with CFO Baird Radford noting that "attach rates to OmniSphere are expected to build over the subsequent years as customers progress away from on-premises solutions." The company remains focused on maintaining operating leverage while navigating ongoing macro and sector-specific uncertainties, such as memory component costs and evolving policy environments.
Key insights from management’s remarks
Management credited the quarter’s results to a blend of operational discipline, expanding sales pipeline, and early momentum in cloud-enabled medication management. Omnicell’s leadership focused on differentiating its offering and supporting customers’ transition to enterprise solutions.
-
Cloud platform advancement: Progress on the OmniSphere cloud-native platform was a focal point, with management emphasizing its growing role in providing enterprise-wide visibility and actionable insights. Early customer feedback highlighted the value of integrating software and hardware to streamline workflows and reduce administrative burden.
-
Automated dispensing cabinet strength: The Titan XT and existing XT platforms continued to serve as foundational products in U.S. hospitals, supporting operational efficiency and reliability. Management noted that product refresh cycles are closely tied to hospitals’ strategic investment priorities.
-
Leasing adoption grows: Omnicell’s expanding leasing program was cited as a key enabler in securing competitive deals, offering financial flexibility to health systems. Management believes leasing now removes barriers to adoption, particularly in competitive environments, though it is not the sole deciding factor in customer wins.
-
Customer engagement deepening: The company reported increased pipeline activity across a range of deal sizes, including notable wins in government and specialty pharmacy channels. Management said customers increasingly view Omnicell’s offerings as strategic enterprise investments, leading to longer evaluation and planning cycles but higher engagement.
-
Cost discipline and margin improvement: CFO Baird Radford attributed stronger margins to a deliberate emphasis on cost efficiency, favorable product and customer mix, and disciplined investment in innovation, noting that operating leverage has begun to materialize even as revenue remains flat.
Drivers of future performance
Omnicell’s outlook is driven by the pace of adoption for its new hardware and cloud platform, tempered by hospital capital spending cycles and evolving policy and cost pressures.
-
Titan XT and OmniSphere rollout: Management sees the roll-out of Titan XT hardware and the scaling of OmniSphere cloud subscriptions as central to future growth. While initial shipments of Titan XT have begun, meaningful revenue contributions are expected to ramp up as more customers refresh their hardware and attach to the cloud platform over several years.
-
Leasing and capital environment: Leasing is expected to remain a key competitive tool, supporting deal flow in an environment where hospitals seek greater financial flexibility. Management anticipates that the mix of leased versus purchased cabinets will evolve, with leases offering a slight gross margin tradeoff upfront but recurring revenue benefits over the life of the agreement.
-
Margin and cost headwinds: Persistent memory component cost inflation and uncertainty around the 340B Drug Pricing Program are cited as ongoing risks. Management expects operating leverage to improve as the product refresh cycle matures, but acknowledges that margin variability may occur quarter to quarter depending on deal timing and customer mix.
Catalysts in upcoming quarters
Looking ahead, the StockStory team will be watching (1) the adoption rate and attach rates for OmniSphere among existing and new Titan XT customers, (2) the pace and mix of leasing versus capital sales in the hospital channel, and (3) margin trends as cost pressures from memory components and policy changes unfold. Execution in competitive wins and continued progress in government and specialty pharmacy channels will also be critical signposts.
Omnicell currently trades at $36.94, up from $35.95 just before the earnings. Is the company at an inflection point that warrants a buy or sell? Find out in our full research report (it’s free).
Our favorite stocks right now
WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don’t just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.
But our AI platform says the party isn’t over. Find out which 9 stocks made the cut this week — FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+1,154% between June 2020 and June 2025). Find your next big winner with StockStory today.